A resource for reactor physicists and engineers and students of nuclear power engineering, this publication provides a comprehensive summary of the thermophysical properties data needed in nuclear ...
An FDA advisory committee has voted that Amgen’s confirmatory phase 3 trial for KRAS inhibitor Lumakras is not enough to support full approval, but it seems unlikely that the first-to-market therapy ...
Acadia Pharma's attempts to extend the indications of its Nuplazid drug in the US to include Alzheimer's disease-related psychosis have suffered another major setback. Nuplazid (pimavanserin) is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback